Amplia Therapeutics (ASX:ATX) Other Current Payables: A$0.09 Mil (As of Mar. 2026)


ASX:ATX Amplia Therapeutics Ltd ASX:ATX
36 GF Score
Price A$0.15
! 2 Warning Signs
View Full Analysis

What is Amplia Therapeutics Other Current Payables?

Amplia Therapeutics ASX:ATX 36 Other Current Payables is A$0.09 Mil as of Mar. 2026. GuruFocus rates ASX:ATX with a GF Score™ of 36/100. The stock has 2 warning signs investors should review.

Amplia Therapeutics's Other Current Payables for the quarter that ended in Mar. 2026 was A$0.09 Mil.

Amplia Therapeutics's quarterly Other Current Payables declined from Mar. 2025 (A$0.24 Mil) to Sep. 2025 (A$0.00 Mil) but then increased from Sep. 2025 (A$0.00 Mil) to Mar. 2026 (A$0.09 Mil).

Amplia Therapeutics's annual Other Current Payables increased from Mar. 2024 (A$0.19 Mil) to Mar. 2025 (A$0.24 Mil) but then declined from Mar. 2025 (A$0.24 Mil) to Mar. 2026 (A$0.09 Mil).

Amplia Therapeutics Other Current Payables Related Terms

Amplia Therapeutics Other Current Payables Historical Data

* Premium members only.

The historical data trend for Amplia Therapeutics's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Amplia Therapeutics Other Current Payables Chart

Amplia Therapeutics Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Other Current Payables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.12 0.18 0.19 0.24 0.09

Amplia Therapeutics Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.19 0.00 0.24 0.00 0.09
ASX:ATX
36GF Score
Amplia Therapeutics Ltd ASX:ATX
Other Current Payables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Amplia Therapeutics Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Frequently Asked Questions Learn more about Other Current Payables →
What does a Other Current Payables of A$0.09 Mil mean?
Amplia Therapeutics (ASX:ATX) has a Other Current Payables of A$0.09 Mil as of Mar. 2026. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Amplia Therapeutics and its competitors.
Is Amplia Therapeutics' Other Current Payables too high?
Amplia Therapeutics' current Other Current Payables is A$0.09 Mil. Overall, Amplia Therapeutics has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does Amplia Therapeutics' Other Current Payables compare to VRTX and REGN?
Amplia Therapeutics' Other Current Payables of A$0.09 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for a Biotechnology company?
A good Other Current Payables depends on the Biotechnology industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Amplia Therapeutics and its competitors. Amplia Therapeutics's current Other Current Payables is A$0.09 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amplia Therapeutics stock overvalued right now?
Amplia Therapeutics (ASX:ATX) has a current Other Current Payables of A$0.09 Mil. The current Other Current Payables is A$0.09 Mil. Amplia Therapeutics' overall GF Score™ is 36/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For Amplia Therapeutics (ASX:ATX), the current Other Current Payables is A$0.09 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Amplia Therapeutics Business Description

Other Exchanges INNMF:USA
Address 90 William Street, Level 5, Melbourne, VIC, AUS, 3000
Amplia Therapeutics Ltd is an Australian, clinical-stage, drug development company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. The company is focused on the development of these drug candidates for potential use in multiple indications in oncology (e.g. pancreatic cancer) and chronic fibrotic diseases. Its molecule, AMP945 is a selective and potent inhibitor of FAK and is currently in a phase 2 clinical trial for pancreatic cancer, in clinical development for ovarian cancer, and preclinical development for idiopathic pulmonary fibrosis (IPF).
36GF Score

Get the complete analysis for ASX:ATX

Other Current Payables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.15
Price